Full-Time

Associate Director

Global Knowledge Management

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

King of Prussia, PA, USA + 2 more

More locations: Municipality of Esplugues de Llobregat, Barcelona, Spain | Waltham, MA, USA

In Person

Master's, PhD

Category
Data & Analytics (1)
Required Skills
Data Governance

Get referred to CSL

See people who can refer or advise you

Requirements
  • A Master of Science, Master of Library and Information Science/Master of Library Science, or Ph.D. in a science-related field such as Biochemistry or Chemistry, or equivalent education and experience in a Knowledge Management environment.
  • At least eight years of experience in the pharmaceutical industry.
  • At least eight years of experience in Knowledge Management, Research and Development, or Medical Affairs.
  • Experience in data standards and governance within life sciences.
  • Extensive understanding of copyright regulations, artificial intelligence, and application programming interface usage.
  • Vendor management and contract negotiation skills focused on research databases and their integration.
  • Professional fluency in English for scientific and technical communication.
  • Ability to understand customer needs and deliver value-creating solutions.
  • Ability to collaborate effectively and influence stakeholders at all organizational levels.
  • Ability to identify and develop key metrics to drive business decisions.
Responsibilities
  • Lead the strategic operations of the information management, knowledge management, and insight advisory service across the CSL Group.
  • Contribute to the CSL Data Standards and governance program through project participation, functional leadership, and information management consultation.
  • Manage internal and external resources supporting operations and key projects for the Digital Information and Knowledge Management Strategy, with a focus on artificial intelligence.
  • Administer, organize, and strategically plan for the Global Knowledge Management team, including policy formulation, budget administration, and personnel management.
  • Manage the cost center for resources, consulting, and data collection subscriptions, including contract development and negotiations.
  • Partner with Global Sourcing in accordance with CSL policy.
  • Ensure CSL has access to information and research that meets business needs, and maximize the value and usage of data collection.
  • Build and maintain professional relationships with internal and external knowledge services, pharmaceutical library resources, industry consortia, and peer networks.
  • Access, share, and apply relevant scientific, regulatory, and industry information to support organizational goals.
  • Lead, develop, and implement emerging information technologies, systems, and workflows to optimize specialized information delivery models and services.
  • Manage vendor relationships and procurement decisions for knowledge resources, databases, and application programming interfaces.
  • Promote digital innovation, value creation, and a data-ownership mindset.
  • Lead globally distributed knowledge team members and empower staff through consultative and transformational leadership, development, coaching, and mentoring.
  • Oversee the operations and performance of global systems and platforms, including internal and external information sources.
  • Manage CSL’s Copyright Agency Limited license.
  • Implement business improvement processes through technology integration, continuous improvement, usage metrics, and quality management principles.
  • Develop performance metrics and programs to monitor and improve services and resource utilization.
  • Negotiate, influence, collaborate, and foster high-level stakeholder relationships across a cross-matrix portfolio to align strategies, enhance performance, and increase operational efficiency.
Desired Qualifications
  • At least five years of experience in people leadership roles in global organizations.
  • At least five years of experience in Global Library Services or a comparable information management responsibility.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FY26 HEMGENIX sales rose 25%, validating CSL’s gene-therapy commercialization engine.
  • CSL completed $176 million in FY26 cost savings, ahead of plan.
  • VarmX’s September 2025 option deal adds a potential $2.1 billion anticoagulation franchise.

What critics are saying

  • FY26 revenue fell 1% and underlying NPATA fell 2% on plasma weakness.
  • China albumin sales dropped 17% in FY26 after government cost-containment measures.
  • Pentagon ended the U.S. flu vaccine mandate in 2026, pressuring Seqirus demand and execution.

What makes CSL unique

  • CSL spans plasma, gene therapy, and influenza vaccines, unlike single-platform biotech peers.
  • HEMGENIX remains the only approved hemophilia B gene therapy across the U.S. and Europe.
  • CSL’s global plasma collection and manufacturing network supports hard-to-replicate immunoglobulin and albumin supply.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...